press release

October 31, 2019

− Achieved Third Quarter 2019 ONPATTRO® Global Net Product Revenues of $46.1 Million, Including Initial Sales in Japan, with Over 600 Patients on Commercial Product Worldwide – − Initiated APOLLO B Phase 3 Study of Patisiran for the Treatment of Hereditary and Wild Type ATTR Amyloidosis with Cardiomyopathy – – Advanced Additional Late Stage Clinical Programs; On Track to Report Topline ...

press release

September 13, 2019

CAMBRIDGE, Mass. (BUSINESS WIRE) Sep. 13, 2019 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented new results from an analysis of the UK Biobank – a prospective cohort study with genetic, physical, and health data on approximately 500,000 individuals across the United Kingdom – demonstrating a significant association of the V122I mutation, a highly prevalent mutation ...

press release

September 3, 2019

− Neurofilament Light Chain (NfL) Identified as a Potential Biomarker of Nerve Damage and Polyneuropathy due to hATTR Amyloidosis; ONPATTRO® (patisiran) Treatment Found to Reduce NfL Levels Relative to Placebo in APOLLO Phase 3 Study– − In Analysis of UK Biobank, Carriers of Transthyretin (TTR) “Stabilizing” T119M Variant in a General Population Setting Show No Evidence for Extended Lifespan or Protection ...

press release

August 6, 2019

− Achieved Second Quarter 2019 ONPATTRO® Global Net Product Revenues of $38.2 Million with More Than 500 Patients on Commercial Product Worldwide – − Reported Positive Results from ENVISION Phase 3 Study of Givosiran, Submitted Regulatory Filings in the U.S. and EU, and Received Priority Review from FDA – – Completed Enrollment in ILLUMINATE A Phase 3 Study of Lumasiran and ...

press release

July 30, 2019

-- Partnership with GENESIS Pharmamarks an important step in the global commercial expansion of ONPATTRO, the first in class ‘gene silencing’ RNAi therapeutic ZUG, Switzerland, and Nicosia, Cyprus, 30 July, 2019 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company and GENESIS Pharma, a leading regional biopharma company operating in the broader region of South East Europe, announced today an ...

press release

June 24, 2019

− Patisiran Global Open Label Extension (OLE) Study Demonstrates Maintained Reversal of Disease Progression and Consistent Safety Profile, with Greater Than Four Years of Patient Experience and Over 6,000 Doses Administered – − APOLLO Patients Previously on Tafamidis Benefited from Patisiran with Improvements in Neuropathy Impairment and Quality of Life – − Indirect Treatment Comparison Results Show Favorable Treatment Effects of ...

press release

May 29, 2019

− Company Appoints Chief Human Resources Officer and Chief Scientific Officer – CAMBRIDGE, Mass. (BUSINESS WIRE) May 29, 2019 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of Kelley Boucher as the Company’s Senior Vice President (SVP), Chief Human Resources Officer (CHRO) and the promotion of Kevin Fitzgerald, Ph.D., as SVP, Chief Scientific Officer (CSO). ...

press release

May 1, 2019

− Achieved First Quarter 2019 ONPATTRO® Global Net Product Revenues of $26.3 Million with Over 400 Patients on Commercial Product Worldwide – − Achieved Positive Results in ENVISION Phase 3 Study of Givosiran – − Formed Broad Collaboration with Regeneron to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases – − Strengthened Balance Sheet ...

press release

April 12, 2019

− Givosiran Achieved a 74 Percent Mean Reduction in Composite Annualized Attack Rate (AAR) Relative to Placebo, with Consistent Reductions Across all Components of Composite Endpoint and Subgroups – − Treatment Effect Includes a 90 Percent Median Decrease in Composite AAR Relative to Placebo, with 50 Percent of Givosiran Patients Attack Free – − Ninety Nine Percent of Patients Enrolled in ...

press release

March 6, 2019

− Givosiran Meets Primary and Majority of Secondary Endpoints, with Significant Reduction in Annualized Rate of Composite Porphyria Attacks Relative to Placebo – − Alnylam Intends to Complete Filing of New Drug Application (NDA) and Marketing Authorisation Application (MAA) in mid 2019 – − Full Results to be Presented at the European Association for the Study of the Liver (EASL) International Liver ...